GLENMARK - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.8
✅ Positive
Glenmark Pharma has shown significant profit growth in the latest quarter, with PAT increasing over tenfold compared to the previous quarter. Furthermore, strong volume suggests continued investor interest and potentially upward momentum within the stock.
⚠️ Limitation
The high P/E ratio of 42.1 indicates that the stock is currently overvalued relative to its earnings, and the PEG ratio of 91.6 further reinforces this concern. The negative DII holding also presents a risk factor.
📉 Company Negative News
Recent news highlights substantial profit growth driven by India and North America businesses, but does not present any significant negative factors beyond the already established high valuation.
📈 Company Positive News
The report indicates a more than tenfold increase in profits due to strong performance in both India and North America markets, signaling positive business developments.
🏭 Industry
The pharmaceutical sector in India is experiencing growth driven by increasing domestic demand and expanding exports, particularly to developed economies like the US and Canada. However, competition within the industry remains intense, and regulatory changes can significantly impact company performance.
🧾 Conclusion
A buy price of 2150 ₹ would be suitable for entry, utilizing the current momentum supported by high volume. Initial exit levels should target a profit-taking point at 2250 ₹, representing a modest gain. Alternatively, implement a stop-loss order at 2130 ₹ to mitigate potential downside risk due to the overvalued status and negative DII holding.